Fig. 2From: Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumoniaThe dynamic changes of the lymphocyte subsets of the patient. The percentage of CD3+ T cell (a), CD4+ T cell (b), and CD8+ T cell (c) and the counts of CD3+ T cell (d), CD4+ T cell (e), and CD8+ T cell (f) were all increased after intravenous injection of hWJCsBack to article page